These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29442177)

  • 21. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
    Mizuno Y; Nomoto M; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N;
    Mov Disord; 2013 Sep; 28(10):1447-50. PubMed ID: 23801585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
    Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.
    Isaacson SH; Boroojerdi B; Waln O; McGraw M; Kreitzman DL; Klos K; Revilla FJ; Heldman D; Phillips M; Terricabras D; Markowitz M; Woltering F; Carson S; Truong D
    Parkinsonism Relat Disord; 2019 Jul; 64():132-137. PubMed ID: 30948242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of intensive multidisciplinary rehabilitation in Parkinson's disease: a randomised controlled study.
    Ferrazzoli D; Ortelli P; Zivi I; Cian V; Urso E; Ghilardi MF; Maestri R; Frazzitta G
    J Neurol Neurosurg Psychiatry; 2018 Aug; 89(8):828-835. PubMed ID: 29321141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor.
    Bhidayasiri R; Sringean J; Chaiwong S; Anan C; Penkeaw N; Leaknok A; Boonpang K; Saksornchai K; Rattanachaisit W; Thanawattano C; Jagota P
    Parkinsonism Relat Disord; 2017 Nov; 44():124-128. PubMed ID: 28818560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
    Nomoto M; Iwaki H; Kondo H; Sakurai M
    J Neurol; 2018 Feb; 265(2):253-265. PubMed ID: 29164312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.
    LeWitt PA; Boroojerdi B; Surmann E; Poewe W; ;
    J Neural Transm (Vienna); 2013 Jul; 120(7):1069-81. PubMed ID: 23208198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients.
    Rossi C; Genovesi D; Marzullo P; Giorgetti A; Filidei E; Corsini GU; Bonuccelli U; Ceravolo R
    Clin Neuropharmacol; 2017; 40(1):34-36. PubMed ID: 27941527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rotigotine: in Parkinson's disease.
    Reynolds NA; Wellington K; Easthope SE
    CNS Drugs; 2005; 19(11):973-81. PubMed ID: 16268667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials.
    Chen F; Jin L; Nie Z
    J Pharm Pharm Sci; 2017; 20(0):285-294. PubMed ID: 28810946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
    Elmer LW; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2012 Jun; 18(5):488-93. PubMed ID: 22326237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
    Giladi N; Boroojerdi B; Surmann E
    J Neural Transm (Vienna); 2013 Sep; 120(9):1321-9. PubMed ID: 23508526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.
    Sun W; Wang Q; Yang T; Feng C; Qu Y; Yang Y; Li C; Sun Z; Asakawa T
    Neurol Sci; 2022 Oct; 43(10):5821-5837. PubMed ID: 35691972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study.
    Pierantozzi M; Placidi F; Liguori C; Albanese M; Imbriani P; Marciani MG; Mercuri NB; Stanzione P; Stefani A
    Sleep Med; 2016 May; 21():140-4. PubMed ID: 27448485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease.
    Wang Y; Yang YC; Lan DM; Wu H-; Zhao ZX
    Sleep Breath; 2017 May; 21(2):319-325. PubMed ID: 27726069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Balance Dysfunction in Parkinson Disease: A Randomized Controlled Study With 6-Month Follow-Up.
    Palamara G; Gotti F; Maestri R; Bera R; Gargantini R; Bossio F; Zivi I; Volpe D; Ferrazzoli D; Frazzitta G
    Arch Phys Med Rehabil; 2017 Jun; 98(6):1077-1085. PubMed ID: 28254636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
    Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
    Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Night-time use of rotigotine in advanced Parkinson's disease.
    Canesi M; Mariani CB; Isaias IU; Pezzoli G
    Funct Neurol; 2010; 25(4):201-4. PubMed ID: 21388580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.
    Schirinzi T; Imbriani P; D'Elia A; Di Lazzaro G; Mercuri NB; Pisani A
    Clin Neurol Neurosurg; 2017 May; 156():63-65. PubMed ID: 28342306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.
    Zhou CQ; Li SS; Chen ZM; Li FQ; Lei P; Peng GG
    PLoS One; 2013; 8(7):e69738. PubMed ID: 23936090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.